# OnCo record b-undruggable-targets (bottleneck). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/bottlenecks/b-undruggable-targets/>
  a schema:Thing ;
  onco:kind "bottleneck" ;
  schema:identifier "b-undruggable-targets" ;
  schema:name "The undruggable drivers"@en ;
  schema:description "The proteins that drive most cancers, such as MYC, mutant p53 and most RAS variants, still have no good drug."@en ;
  schema:url <https://onco.cc/bottlenecks/b-undruggable-targets/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/nrc.2017.36>, <https://www.cancer.gov/research/key-initiatives/ras>, <https://doi.org/10.1158/0008-5472.CAN-19-3682> ;
  onco:related <https://onco.cc/roadmaps/kras-roadmap/>, <https://onco.cc/ideas/idea-ras-inhibitor-neoadjuvant-pdac/>, <https://onco.cc/ideas/idea-shared-kras-vaccine-adjuvant/>, <https://onco.cc/collections/depmap/>, <https://onco.cc/collections/open-targets/>, <https://onco.cc/ideas/idea-bio1-myc-max-molecular-glue/>, <https://onco.cc/ideas/idea-bio1-omomyc-mrna/>, <https://onco.cc/ideas/idea-bio1-p53-mutant-reactivator-expansion/>, <https://onco.cc/ideas/idea-bio1-mutant-p53-degrader/>, <https://onco.cc/ideas/idea-bio1-pan-ras-covalent-g12d/>, <https://onco.cc/ideas/idea-bio1-covalent-ligandability-atlas/>, <https://onco.cc/ideas/idea-bio1-glue-degrader-atlas/>, <https://onco.cc/ideas/idea-bio1-fusion-tf-degraders/>, <https://onco.cc/ideas/idea-bio1-condensate-disruptors/>, <https://onco.cc/ideas/idea-bio1-tumour-restricted-e3-atlas/>, <https://onco.cc/ideas/idea-bio1-antibody-degrader-conjugates/>, <https://onco.cc/ideas/idea-bio1-lytac-surface-degraders/>, <https://onco.cc/ideas/idea-bio1-rna-targeting-small-molecules/>, <https://onco.cc/ideas/idea-bio1-epigenetic-silencing-in-vivo/>, <https://onco.cc/ideas/idea-bio1-paralog-synthetic-lethality/>, <https://onco.cc/ideas/idea-bio1-pp2a-activators/>, <https://onco.cc/ideas/idea-bio1-wrn-msi-programme/>, <https://onco.cc/ideas/idea-bio1-macrocycle-ppi-campaign/>, <https://onco.cc/ideas/idea-bio1-arv7-degrader/>, <https://onco.cc/ideas/idea-bio1-ai-binders-disordered-regions/>, <https://onco.cc/ideas/idea-bio1-pmhc-bispecifics-public-drivers/>, <https://onco.cc/ideas/idea-bio1-mrna-intrabodies/>, <https://onco.cc/ideas/idea-bio1-translation-dependency-myc/>, <https://onco.cc/ideas/idea-bio1-undruggable-open-consortium/>, <https://onco.cc/ideas/idea-bio1-undruggable-market-commitment/>, <https://onco.cc/ideas/idea-moon-synthetic-lethality-map-every-driver/>, <https://onco.cc/ideas/idea-moon-open-degrader-consortium/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/antisense-sirna/>, <https://onco.cc/technologies/synthetic-lethality-approaches/>, <https://onco.cc/technologies/ai-drug-design/>, <https://onco.cc/technologies/shared-antigen-vaccine/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/menin/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/kmt2a/>, <https://onco.cc/targets/npm1/> ;
  onco:drugs <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/mrtx1133/>, <https://onco.cc/drugs/zoldonrasib/>, <https://onco.cc/drugs/elironrasib/>, <https://onco.cc/drugs/revumenib/>, <https://onco.cc/drugs/ziftomenib/>, <https://onco.cc/drugs/eli-002-7p/>, <https://onco.cc/drugs/eprenetapopt/> ;
  onco:companies <https://onco.cc/companies/revolution-medicines/>, <https://onco.cc/companies/arvinas/>, <https://onco.cc/companies/kymera/>, <https://onco.cc/companies/nurix/>, <https://onco.cc/companies/c4-therapeutics/>, <https://onco.cc/companies/monte-rosa/>, <https://onco.cc/companies/quanta-therapeutics/>, <https://onco.cc/companies/frontier-medicines/>, <https://onco.cc/companies/elicio-therapeutics/> ;
  onco:institutions <https://onco.cc/institutions/nci/>, <https://onco.cc/institutions/broad-institute/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:trials <https://onco.cc/trials/rasolute-302/>, <https://onco.cc/trials/codebreak-200/>, <https://onco.cc/trials/krystal-12/>, <https://onco.cc/trials/amplify-7p/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-dang-nat-rev-cancer/>, <https://onco.cc/key-papers/paper-prior-cancer-res/> .